As the House
of Representative debates a Medicare prescription drug bill this
week, Congressman Ron Paul responded to efforts by the pharmaceutical
industry to block changes that would lower the cost of medicine
for millions of Americans. Paul strongly supports changes to FDA
regulations that would allow prescription drugs to be reimported
from foreign countries, where widely-used drugs often sell for
much less than in the U.S. Paul, a medical doctor for nearly 40
years, is an advocate of innovative market-based solutions to
rising drug costs. He is a member of the House Caucus for Affordable
Pharmaceuticals, which seeks to eliminate rules and regulations
that benefit drug companies at the expense of consumers.
Drug
reimportation is critical to lowering prices, Paul stated.
Reimportation allows American consumers, particularly seniors,
to benefit from worldwide price competition. Its outrageous
that the FDA does not permit U.S. citizens to reimport drugs that
sell for 30 to 300 percent less outside our borders. The pharmaceutical
companies should not be allowed to profit by this government-enforced
price fixing. How much longer should American consumers be expected
to pay much higher prices for identical drugs available in Europe,
Canada, and Mexico for a fraction of the cost?
Paul supports
tax credits for seniors to offset the cost of needed medicines,
and medical savings accounts to allow tax-free savings to be used
to pay for prescriptions. He also supports legislation that streamlines
the FDA approval process to make promising new drugs available
more quickly.
Government
red tape is a major culprit in rising drug costs, Paul concluded.
Congress needs to end subsidies to the pharmaceutical and
insurance industries, cut unnecessary FDA regulations, and repeal
rules that stifle price competition.